We are live on
!
Find out more
CCM
Catapult Capital Management Portfolio holdings
AUM
$265M
1-Year Est. Return
21.83%
This Fund
S&P 500
This Quarter
Est. Return
+5.74%
1 Year Est. Return
+21.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$696M
AUM Growth
-$122M
(-15%)
Cap. Flow
-$135M
Cap. Flow
% of AUM
-19.45%
Top 10 Holdings %
Top 10 Hldgs %
23.76%
Holding
329
New
119
Increased
34
Reduced
64
Closed
111
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoetis
ZTS
|
+$23.2M |
| 2 |
PepsiCo
PEP
|
+$13.1M |
| 3 |
AbbVie
ABBV
|
+$10.1M |
| 4 |
Elevance Health
ELV
|
+$9.59M |
| 5 |
Abbott
ABT
|
+$8.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$22.4M |
| 2 |
Pfizer
PFE
|
+$18M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$13.1M |
| 4 |
Pediatrix Medical
MD
|
+$11.2M |
| 5 |
Danaher
DHR
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.68% |
| 2 | Consumer Discretionary | 8.46% |
| 3 | Industrials | 7.26% |
| 4 | Consumer Staples | 5.08% |
| 5 | Communication Services | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MON
176
DELISTED
Monsanto Co
MON
| $911K | 0.13% |
+8,548
| New | +$992K |
|
177
Netflix
NFLX
$305B
| $867K | 0.12% |
+92,330
| New | +$773K |
|
178
Viatris
VTRS
$20.7B
| $854K | 0.12% |
12,591
-23,342
| -65% | -$1.65M |
|
|
MRC
179
DELISTED
MRC Global
MRC
| $851K | 0.12% |
+55,123
| New | +$832K |
|
180
Marathon Petroleum
MPC
$91.7B
| $845K | 0.12% |
+16,161
| New | +$822K |
|
181
Oxford Industries
OXM
$571M
| $778K | 0.11% |
8,893
-5,408
| -38% | -$429K |
|
182
Trane Technologies
TT
$97.3B
| $767K | 0.11% |
11,383
-4,961
| -30% | -$340K |
|
183
Kirby Corp
KEX
$7.08B
| $766K | 0.11% |
+9,995
| New | +$792K |
|
184
Vanda Pharmaceuticals
VNDA
$312M
| $761K | 0.11% |
+60,000
| New | +$647K |
|
185
CALL
NCR Voyix
VYX
$1.12B
| $753K | 0.11% |
+40,750
| New | +$753K |
|
186
CALL
H&R Block
HRB
$5.61B
| $741K | 0.11% |
25,000
-55,000
| -69% | -$1.73M |
|
187
Masco
MAS
$14.2B
| $735K | 0.11% |
+31,360
| New | +$742K |
|
188
Vulcan Materials
VMC
$35.1B
| $726K | 0.1% |
8,651
-9,399
| -52% | -$820K |
|
|
WBC
189
DELISTED
WABCO HOLDINGS INC.
WBC
| $714K | 0.1% |
5,774
-13,059
| -69% | -$1.64M |
|
190
Charles River Laboratories
CRL
$11.3B
| $703K | 0.1% |
10,000
-35,000
| -78% | -$2.59M |
|
191
Mine Safety
MSA
$6.73B
| $689K | 0.1% |
+14,208
| New | +$681K |
|
|
GNMK
192
DELISTED
GenMark Diagnostics, Inc
GNMK
| $680K | 0.1% |
75,000
-35,000
| -32% | -$353K |
|
193
Quanta Services
PWR
$98.7B
| $611K | 0.09% |
+21,192
| New | +$620K |
|
194
Globalstar
GSAT
$10.3B
| $604K | 0.09% |
+19,086
| New | +$742K |
|
|
MASI
195
DELISTED
Masimo
MASI
| $581K | 0.08% |
15,000
-50,000
| -77% | -$1.79M |
|
196
Aecom
ACM
$9.22B
| $563K | 0.08% |
+17,015
| New | +$562K |
|
197
Martin Marietta Materials
MLM
$32.4B
| $543K | 0.08% |
3,838
-3,323
| -46% | -$484K |
|
|
RAD
198
DELISTED
Rite Aid Corporation
RAD
| $531K | 0.08% |
3,178
-21
| -0.7% | -$3.52K |
|
199
Ligand Pharmaceuticals
LGND
$5.94B
| $505K | 0.07% |
8,015
-8,015
| -50% | -$437K |
|
200
Valero Energy
VLO
$92.6B
| $500K | 0.07% |
+7,982
| New | +$471K |
|
Similar funds
LOCB
AF
TCOTO
DCM
SCA
LPVHS
ATC
TFF
Catapult Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Catapult Capital Management held 329 positions worth $696M, down 15% from $818M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Catapult Capital Management withdrew a net $135M in Q2 2015, closing 111 positions and reducing 64 holdings. Its most notable exit was Pfizer, an estimated $18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Catapult Capital Management opened a new position in Zoetis worth $23.5M.
- Catapult Capital Management's largest Q2 2015 buy was Zoetis: 486,665 shares worth $23.5M.
- Catapult Capital Management added most to AbbVie in Q2 2015, an estimated $10.1M increase.
- Catapult Capital Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $22.4M.
- Catapult Capital Management fully exited Pfizer in Q2 2015, selling an estimated $18M.
- Catapult Capital Management's ten largest holdings make up 24% of its $696M portfolio in Q2 2015.
- Catapult Capital Management opened 119 new positions and closed 111 in Q2 2015.
- Catapult Capital Management's portfolio value fell 15% quarter-over-quarter to $696M.
Based on Catapult Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.